FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2758021947> ?p ?o ?g. }

• W2758021947 endingPage "230" @default.
• W2758021947 startingPage "225" @default.
• W2758021947 abstract "To examine visual outcomes and recurrence rates in patients with choroidal neovascularization (CNV) resulting from neovascular age-related macular degeneration (nAMD) with successful cessation of therapy using a treat-extend-stop (TES) protocol.Cohort study.Three hundred eighty-five eyes of 321 patients with nAMD identified in clinical practice and treated with a TES protocol between 2008 and 2016.Retrospective review of patients initially managed with 3 anti-vascular endothelial growth factor (VEGF) injections at 4-week intervals; treatment was extended if the macula remained dry based on spectral-domain OCT, using a TES protocol. Treatment was stopped if warranted and was reinitiated if there was a new or recurrent CNV.Percentage of eyes meeting criteria for treatment cessation and percentage experiencing recurrence after treatment cessation, average time to recurrence, and visual function at each of these time points, including recovery of vision after reinstitution of therapy.A total of 37.3% of eyes met criteria for treatment cessation, with an average follow-up of 27 months. Overall recurrence rate was 29.4% at a mean time interval of 14 months for patients who stopped anti-VEGF therapy. In those patients whose CNV recurred, 54.8% recurred in the first year and 26.2% recurred in the second year after treatment was stopped. Average initial vision was 20/70 and improved to 20/50 (P < 0.001) after patients met criteria for cessation of therapy. A mean loss of vision occurred with recurrence (20/60; P < 0.003). However, once therapy was reinitiated, visual acuity recovered to the level at TES completion and wasn't statistically different than at final treatment (20/50; P < 0.34). Overall, 54.8% of eyes that demonstrated a recurrence of CNV had final vision of 20/40 or better compared with 45% of patients at the time of recurrence and 60% before recurrence.After completing the TES protocol, 29.4% of patients showed recurrence of CNV. Patients who lost vision with recurrence recovered to the level of vision at treatment cessation with reinstitution of therapy. Patients managed with a TES protocol may stop therapy successfully and maintain improved vision even if the CNV recurs." @default.
• W2758021947 created "2017-10-06" @default.
• W2758021947 creator A5030763962 @default.
• W2758021947 creator A5047968636 @default.
• W2758021947 creator A5056605813 @default.
• W2758021947 creator A5060562539 @default.
• W2758021947 date "2018-03-01" @default.
• W2758021947 modified "2023-09-29" @default.
• W2758021947 title "Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat–Extend–Stop Protocol" @default.
• W2758021947 cites W1481978003 @default.
• W2758021947 cites W1500728559 @default.
• W2758021947 cites W160762057 @default.
• W2758021947 cites W1967851714 @default.
• W2758021947 cites W1968773603 @default.
• W2758021947 cites W1973149924 @default.
• W2758021947 cites W1995067794 @default.
• W2758021947 cites W1996171994 @default.
• W2758021947 cites W2004117352 @default.
• W2758021947 cites W2011751119 @default.
• W2758021947 cites W2016225811 @default.
• W2758021947 cites W2041610458 @default.
• W2758021947 cites W2052102026 @default.
• W2758021947 cites W2061213434 @default.
• W2758021947 cites W2073370253 @default.
• W2758021947 cites W2078432212 @default.
• W2758021947 cites W2079843091 @default.
• W2758021947 cites W2083043469 @default.
• W2758021947 cites W2102946567 @default.
• W2758021947 cites W2121058595 @default.
• W2758021947 cites W2124415048 @default.
• W2758021947 cites W2171962482 @default.
• W2758021947 cites W2172453889 @default.
• W2758021947 cites W2178063321 @default.
• W2758021947 cites W2266679784 @default.
• W2758021947 cites W2311124170 @default.
• W2758021947 cites W2325448373 @default.
• W2758021947 cites W2332541498 @default.
• W2758021947 cites W2343042175 @default.
• W2758021947 cites W2530348241 @default.
• W2758021947 cites W2539171747 @default.
• W2758021947 cites W4250031098 @default.
• W2758021947 cites W4256101427 @default.
• W2758021947 doi "https://doi.org/10.1016/j.oret.2017.07.009" @default.
• W2758021947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31047590" @default.
• W2758021947 hasPublicationYear "2018" @default.
• W2758021947 type Work @default.
• W2758021947 sameAs 2758021947 @default.
• W2758021947 citedByCount "37" @default.
• W2758021947 countsByYear W27580219472018 @default.
• W2758021947 countsByYear W27580219472019 @default.
• W2758021947 countsByYear W27580219472020 @default.
• W2758021947 countsByYear W27580219472021 @default.
• W2758021947 countsByYear W27580219472022 @default.
• W2758021947 countsByYear W27580219472023 @default.
• W2758021947 crossrefType "journal-article" @default.
• W2758021947 hasAuthorship W2758021947A5030763962 @default.
• W2758021947 hasAuthorship W2758021947A5047968636 @default.
• W2758021947 hasAuthorship W2758021947A5056605813 @default.
• W2758021947 hasAuthorship W2758021947A5060562539 @default.
• W2758021947 hasConcept C118487528 @default.
• W2758021947 hasConcept C126322002 @default.
• W2758021947 hasConcept C141071460 @default.
• W2758021947 hasConcept C167135981 @default.
• W2758021947 hasConcept C2776403814 @default.
• W2758021947 hasConcept C2776694085 @default.
• W2758021947 hasConcept C2777802072 @default.
• W2758021947 hasConcept C2778257484 @default.
• W2758021947 hasConcept C2778271429 @default.
• W2758021947 hasConcept C2780394083 @default.
• W2758021947 hasConcept C2781100027 @default.
• W2758021947 hasConcept C2781359195 @default.
• W2758021947 hasConcept C71924100 @default.
• W2758021947 hasConcept C72563966 @default.
• W2758021947 hasConceptScore W2758021947C118487528 @default.
• W2758021947 hasConceptScore W2758021947C126322002 @default.
• W2758021947 hasConceptScore W2758021947C141071460 @default.
• W2758021947 hasConceptScore W2758021947C167135981 @default.
• W2758021947 hasConceptScore W2758021947C2776403814 @default.
• W2758021947 hasConceptScore W2758021947C2776694085 @default.
• W2758021947 hasConceptScore W2758021947C2777802072 @default.
• W2758021947 hasConceptScore W2758021947C2778257484 @default.
• W2758021947 hasConceptScore W2758021947C2778271429 @default.
• W2758021947 hasConceptScore W2758021947C2780394083 @default.
• W2758021947 hasConceptScore W2758021947C2781100027 @default.
• W2758021947 hasConceptScore W2758021947C2781359195 @default.
• W2758021947 hasConceptScore W2758021947C71924100 @default.
• W2758021947 hasConceptScore W2758021947C72563966 @default.
• W2758021947 hasIssue "3" @default.
• W2758021947 hasLocation W27580219471 @default.
• W2758021947 hasLocation W27580219472 @default.
• W2758021947 hasOpenAccess W2758021947 @default.
• W2758021947 hasPrimaryLocation W27580219471 @default.
• W2758021947 hasRelatedWork W1995044506 @default.
• W2758021947 hasRelatedWork W2042956061 @default.
• W2758021947 hasRelatedWork W2049577742 @default.
• W2758021947 hasRelatedWork W2054981704 @default.
• W2758021947 hasRelatedWork W2068871928 @default.
• W2758021947 hasRelatedWork W2227583243 @default.

• next